Showing results (221-230 of 1,028) with videos related to

Sort By:
Pageof 103
The Lancet. Respiratory Medicine|September 22, 2025
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised studyShun Lu, Oleksandr Vynnychenko, Yaroslav Kulyaba, et al.
The Lancet. Respiratory Medicine|July 20, 2025
Global epidemiology and burden of interstitial lung diseasePaolo Spagnolo, Sabina A Guler, Nazia Chaudhuri, et al.
The Lancet. Respiratory Medicine|August 4, 2025
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cross-sectional studyLaura Garriga-Grimau, Ahmad Kantar, Keith Grimwood, et al.
The Lancet. Respiratory Medicine|October 2, 2025
Genetic and environmental risk factors for asthma: towards preventionGerard H Koppelman, Maria Pino-Yanes, Erik Melén, et al.
The Lancet. Respiratory Medicine|May 2, 2025
Defining and subphenotyping ARDS: insights from an international Delphi expert panelPrashant Nasa, Lieuwe D Bos, Elisa Estenssoro, et al.
The Lancet. Respiratory Medicine|May 27, 2023
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 studyShun Lu, Jianying Zhou, Hong Jian, et al.
The Lancet. Respiratory Medicine|March 21, 2024
Association of active mobilisation variables with adverse events and mortality in patients requiring mechanical ventilation in the intensive care unit: a systematic review and meta-analysisMichelle Paton, Sarah Chan, Ary Serpa Neto, et al.
The Lancet. Respiratory Medicine|March 29, 2024
High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trialRovina Ruslami, Federica Fregonese, Lika Apriani, et al.
The Lancet. Respiratory Medicine|November 29, 2025
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trialDavid J Jackson, Njira L Lugogo, Mark Gurnell, et al.
The Lancet. Respiratory Medicine|March 24, 2026
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trialMalcolm G Semple, Chloe Donohue, Laura Price, et al.
Pageof 103